ArticleBlood advances2024

Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.

Gaia Gentile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.